Abstract
Small interfering RNA (siRNA) is a promising tool for gene therapy-based disease treatments. However, delivery of siRNA to the target cells requires a specific and reliable carrier system. Herein we describe a targeted carrier system that can deliver siRNA to cancer cells overexpressing the human epidermal growth factor 2 (HER2) receptor. Trastuzumab-conjugated poly(amido)amine dendrimers can be synthesized using the protocols described here.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Xin Y, Huang M, Guo MM et al (2017) Nano-based delivery of RNAi in cancer therapy. Mol Cancer 16:134
Fellmann C, Lowe SW (2014) Stable RNA interference rules for silencing. Nat Cell Biol 16(1):10–18
Scherman D, Rousseau A, Bigey P et al (2017) Genetic pharmacology: progresses in siRNA delivery and therapeutic applications. Gene Ther 24:151–156
Haussecker D (2014) Current issues of RNAi therapeutics delivery and development. J Control Release 195:49–54
Mizrahy S, Hazan-Halevy I, Dammes N et al (2017) Current progress in non-viral RNAi-based delivery strategies to lymphocytes. Mol Ther 25:1–10
Wang J, Lu Z, Wientjes MG et al (2010) Delivery of siRNA therapeutics: barriers and carriers. AAPS J 12:492–503
Ozpolat B, Sood AK, Lopez-Berestein G (2014) Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 66:110–116
Wu SY, Lopez-Berestein G, Calin GA et al (2014) RNAi therapies: drugging the undruggable. Sci Transl Med 6(240):240ps7
Yang J, Zhang Q, Chang H, Cheng Y (2015) Surface-engineered dendrimers in gene delivery. Chem Rev 115:5274–5300
Biswas S, Torchilin VP (2013) Dendrimers for siRNA delivery. Pharmaceuticals 6:161–183
Zhou J, Wu J, Hafdi N et al (2006) PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun (Camb) 22:2362–2364
Senkusa E, Cardosob F, Pagani O (2014) Time for more optimism in metastatic breast cancer? Cancer Treat Rev 40:220–228
Sampathkumar SG, Yarema KJ (2007) Dendrimers in cancer treatment and diagnosis. In: Kumar CSSR (ed) Nanotechnologies for the life sciences, vol 7. Wiley-VCH, Weinheim
Figueroa-Magalhães MC, Jelovac D, Connolly RM, Wolff AC (2014) Treatment of HER2-positive breast cancer. Breast 23:128–136
Kulhari H, Pooja D, Rompicharla SVK et al (2015) Biomedical applications of Trastuzumab: as a therapeutic agent and a targeting ligand. Med Res Rev 35:849–876
Kulhari H, Pooja D, Shrivastava S et al (2015) Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer. Sci Rep 6:23179
Acknowledgments
H.K. acknowledges the Department of Science and Technology, New Delhi, for INSPIRE Faculty Award. A.K.J. acknowledges the University Grants Commission, New Delhi, for Ph.D. scholarship.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Kulhari, H., Jangid, A.K., Adams, D.J. (2019). Monoclonal Antibody-Conjugated Dendritic Nanostructures for siRNA Delivery. In: Dinesh Kumar, L. (eds) RNA Interference and Cancer Therapy. Methods in Molecular Biology, vol 1974. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9220-1_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9220-1_14
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9219-5
Online ISBN: 978-1-4939-9220-1
eBook Packages: Springer Protocols